NO327154B1 - Andvendelse av luteiniserende hormon i fremstilling av medikament for indusering av multippel follikulogenese. - Google Patents
Andvendelse av luteiniserende hormon i fremstilling av medikament for indusering av multippel follikulogenese. Download PDFInfo
- Publication number
- NO327154B1 NO327154B1 NO20040990A NO20040990A NO327154B1 NO 327154 B1 NO327154 B1 NO 327154B1 NO 20040990 A NO20040990 A NO 20040990A NO 20040990 A NO20040990 A NO 20040990A NO 327154 B1 NO327154 B1 NO 327154B1
- Authority
- NO
- Norway
- Prior art keywords
- day
- fsh
- administered
- administration
- dose
- Prior art date
Links
- 108010073521 Luteinizing Hormone Proteins 0.000 title claims description 100
- 102000009151 Luteinizing Hormone Human genes 0.000 title claims description 100
- 229940040129 luteinizing hormone Drugs 0.000 title claims description 100
- 239000003814 drug Substances 0.000 title claims description 10
- 229940079593 drug Drugs 0.000 title claims description 5
- 230000001939 inductive effect Effects 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 claims description 17
- 230000000638 stimulation Effects 0.000 claims description 16
- 230000002045 lasting effect Effects 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 65
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 65
- 229940028334 follicle stimulating hormone Drugs 0.000 description 65
- 239000012071 phase Substances 0.000 description 27
- 230000016087 ovulation Effects 0.000 description 20
- 230000004936 stimulating effect Effects 0.000 description 19
- 210000000287 oocyte Anatomy 0.000 description 15
- 239000000556 agonist Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 8
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 7
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 7
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 229960005309 estradiol Drugs 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 229930182833 estradiol Natural products 0.000 description 5
- 229940094892 gonadotropins Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 230000008217 follicular development Effects 0.000 description 4
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 3
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 229940046989 clomiphene citrate Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 108010006578 follitropin alfa Proteins 0.000 description 3
- 239000002474 gonadorelin antagonist Substances 0.000 description 3
- 229940057854 gonal f Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000029849 luteinization Effects 0.000 description 3
- 239000003539 oral contraceptive agent Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012502 diagnostic product Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000011599 ovarian follicle development Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 108010055450 with HCG C-terminal peptide human follicle stimulating hormone Proteins 0.000 description 2
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 206010068042 Premature ovulation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960005064 buserelin acetate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010067479 inhibin B Proteins 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940086546 synarel Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01307755 | 2001-09-12 | ||
| PCT/GB2002/004147 WO2003022301A2 (en) | 2001-09-12 | 2002-09-12 | Use of lh in controlled ovarian hyperstimulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20040990L NO20040990L (no) | 2004-03-08 |
| NO327154B1 true NO327154B1 (no) | 2009-05-04 |
Family
ID=8182260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040990A NO327154B1 (no) | 2001-09-12 | 2004-03-08 | Andvendelse av luteiniserende hormon i fremstilling av medikament for indusering av multippel follikulogenese. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7341989B2 (ru) |
| EP (1) | EP1434600B1 (ru) |
| JP (1) | JP2005504072A (ru) |
| KR (1) | KR20040032953A (ru) |
| CN (1) | CN1302806C (ru) |
| AR (1) | AR036591A1 (ru) |
| AT (1) | ATE427755T1 (ru) |
| AU (1) | AU2002331939B2 (ru) |
| BR (1) | BR0212502A (ru) |
| CA (1) | CA2457067A1 (ru) |
| CY (1) | CY1110487T1 (ru) |
| DE (1) | DE60231892D1 (ru) |
| DK (1) | DK1434600T3 (ru) |
| EA (1) | EA009210B1 (ru) |
| ES (1) | ES2322136T3 (ru) |
| HK (1) | HK1067866A1 (ru) |
| HR (1) | HRP20040070A2 (ru) |
| IL (1) | IL160781A0 (ru) |
| ME (1) | MEP38808A (ru) |
| MX (1) | MXPA04002125A (ru) |
| NO (1) | NO327154B1 (ru) |
| PL (1) | PL205472B1 (ru) |
| PT (1) | PT1434600E (ru) |
| RS (1) | RS51505B (ru) |
| SI (1) | SI1434600T1 (ru) |
| UA (1) | UA78970C2 (ru) |
| WO (1) | WO2003022301A2 (ru) |
| ZA (1) | ZA200401008B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050058285A (ko) * | 2002-06-07 | 2005-06-16 | 아레스 트레이딩 에스.에이. | 조절된 난소 과자극 방법 및 이런 방법에 이용되는제약학적 키트 |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| CN102296047B (zh) * | 2011-08-13 | 2013-03-13 | 新疆农垦科学院 | 利用羔羊超排卵母细胞生产体外胚胎的方法 |
| US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| US9282995B2 (en) * | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| RU2629871C1 (ru) * | 2016-03-22 | 2017-09-04 | Сергей Михайлович Юдин | Препарат для стимуляции фолликулогенеза и способ его применения |
| IT202000022015A1 (it) * | 2020-09-18 | 2022-03-18 | Marca Antonio La | Nuovo uso dell'ormone luteinizzante |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4589402A (en) | 1984-07-26 | 1986-05-20 | Serono Laboratories, Inc. | Method of in vitro fertilization |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| WO2000067778A1 (en) * | 1999-05-07 | 2000-11-16 | Applied Research Systems Ars Holding N.V. | Gonadotrophins |
-
2002
- 2002-09-12 KR KR10-2004-7002589A patent/KR20040032953A/ko not_active Application Discontinuation
- 2002-09-12 ME MEP-388/08A patent/MEP38808A/xx unknown
- 2002-09-12 PT PT02767637T patent/PT1434600E/pt unknown
- 2002-09-12 ES ES02767637T patent/ES2322136T3/es not_active Expired - Lifetime
- 2002-09-12 AR ARP020103455A patent/AR036591A1/es not_active Application Discontinuation
- 2002-09-12 PL PL367343A patent/PL205472B1/pl unknown
- 2002-09-12 US US10/487,423 patent/US7341989B2/en not_active Expired - Fee Related
- 2002-09-12 DE DE60231892T patent/DE60231892D1/de not_active Expired - Lifetime
- 2002-09-12 CN CNB028175743A patent/CN1302806C/zh not_active Expired - Fee Related
- 2002-09-12 MX MXPA04002125A patent/MXPA04002125A/es active IP Right Grant
- 2002-09-12 WO PCT/GB2002/004147 patent/WO2003022301A2/en active Application Filing
- 2002-09-12 EP EP02767637A patent/EP1434600B1/en not_active Revoked
- 2002-09-12 AT AT02767637T patent/ATE427755T1/de active
- 2002-09-12 EA EA200400428A patent/EA009210B1/ru not_active IP Right Cessation
- 2002-09-12 AU AU2002331939A patent/AU2002331939B2/en not_active Ceased
- 2002-09-12 RS YUP-212/04A patent/RS51505B/sr unknown
- 2002-09-12 JP JP2003526429A patent/JP2005504072A/ja active Pending
- 2002-09-12 SI SI200230815T patent/SI1434600T1/sl unknown
- 2002-09-12 BR BR0212502-1A patent/BR0212502A/pt not_active Application Discontinuation
- 2002-09-12 IL IL16078102A patent/IL160781A0/xx unknown
- 2002-09-12 DK DK02767637T patent/DK1434600T3/da active
- 2002-09-12 CA CA002457067A patent/CA2457067A1/en not_active Withdrawn
- 2002-12-09 UA UA2004031858A patent/UA78970C2/ru unknown
-
2004
- 2004-01-23 HR HR20040070A patent/HRP20040070A2/hr not_active Application Discontinuation
- 2004-02-06 ZA ZA2004/01008A patent/ZA200401008B/en unknown
- 2004-03-08 NO NO20040990A patent/NO327154B1/no not_active IP Right Cessation
-
2005
- 2005-02-22 HK HK05101453A patent/HK1067866A1/xx not_active IP Right Cessation
-
2009
- 2009-06-30 CY CY20091100694T patent/CY1110487T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7405197B2 (en) | Use of hCG in controlled ovarian hyperstimulation | |
| NO327154B1 (no) | Andvendelse av luteiniserende hormon i fremstilling av medikament for indusering av multippel follikulogenese. | |
| AU2002331939A1 (en) | Use of LH in controlled ovarian hyperstimulation | |
| EP1425033B1 (en) | Use of hcg and lh in controlled ovarian hyperstimulation | |
| Tay | Use of gonadotrophin-releasing hormone agonists to trigger ovulation | |
| US7815912B2 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| CZ20022555A3 (cs) | Farmaceutický prostředek | |
| JP2003520823A5 (ru) | ||
| TW202210096A (zh) | 治療不育症之方法 | |
| Meridis et al. | Drugs in reproductive medicine | |
| AU2002324183B2 (en) | Use of hCG and LH in controlled ovarian hyperstimulation | |
| Lavery | Drugs used in reproductive medicine | |
| Allahbadia et al. | Induction Protocols of the 2000s Using r-hLH and r-hCG | |
| Marín et al. | Potential use of kisspeptin in ovarian stimulation treatments | |
| AU2002324183A1 (en) | Use of hCG and LH in controlled ovarian hyperstimulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
| MM1K | Lapsed by not paying the annual fees |